title: 123I-MIBG Imaging: Patient Preparation and Technologist's Role.
abstract: The radiopharmaceutical (123)I-metaiodobenzylguanidine (MIBG) was approved by the Food and Drug Administration in March 2013 for the assessment of myocardial sympathetic innervation in the evaluation of patients with heart failure and an ejection fraction of no more than 35%. Almost any well-equipped nuclear medicine or nuclear cardiology laboratory can perform this test, although there is a need for special attention to patient preparation, dose calibration, and proper timing of the image acquisition. This article reviews the role of the nuclear medicine technologist and some practical aspects of cardiac sympathetic (123)I-MIBG imaging of which the laboratory team needs to be mindful.
authors.affiliation: Saint Luke's Mid America Heart Institute and Saint Luke's Cardiovascular Consultants, Kansas City, Missouri svanvickle@saint-lukes.org.
authors.forename: S Seth
authors.initials: SS
authors.lastname: Van Vickle
authors.affiliation: Saint Luke's Mid America Heart Institute and Saint Luke's Cardiovascular Consultants, Kansas City, Missouri.
authors.forename: Randall C
authors.initials: RC
authors.lastname: Thompson
mesh_terms: D019797:3-Iodobenzylguanidine; D003952:Diagnostic Imaging / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D017056:Medical Laboratory Personnel; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine
keywords:    123I-MIBG; cardiac denervation; cardiac sympathetic imaging; techniques for MIBG imaging